Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Incontinence & Overactive Bladder Health Center

Font Size

Experimental Drug Targets Overactive Bladder

Mirabegron Is the First Drug in a New Class of OAB Medications
WebMD Health News
Reviewed by Laura J. Martin, MD

May 17, 2011 -- An experimental drug may help improve symptoms and quality of life among the estimated 33 million people who live with overactive bladder (OAB).

OAB is marked by frequent urges to urinate, leakage, and the need to make several trips to the bathroom during the night. It is caused by an involuntary contraction of bladder muscle that occurs as the bladder fills up.

Mirabegron is part of a new class of medications that stimulates cells in the bladder's detrusor muscle to facilitate the proper filling and storage of urine in the bladder.

According to new data presented at the annual meeting of the American Urological Association (AUA) in Washington, D.C., people with OAB who took the new drug showed improvements in the number of leaks and frequency of urination when compared with those who took a placebo. People who took mirabegron scored higher on quality-of-life issues across the board compared with people who took a placebo.

Drug manufacturer Astellas Pharma funded the new study and expects to file for FDA approval in the coming months.

Mirabegron Works Differently Than Other OAB Drugs

The new drug may fill an important niche in OAB treatment. Other OAB drugs are part of a class called anticholinergics. They block the nerves that control bladder muscle contractions and allow for relaxation of the bladder smooth muscle. Side effects of these drugs include dry mouth and constipation.

“All of the treatments that we currently offer work by the same mechanism of action and they all share the same side effects, so when you have a patient in whom anticholinergic medications don’t work or who can’t tolerate them, you have nowhere else to go in the realm of medications,” explains study researcher Victor Nitti, MD, a professor of urology at New York University’s Langone Medical Center in New York City.

“This new class of medication gives us a new way to treat the problem that works by a different mechanism,” he says. The side effect profile is also different. “We don’t see dry mouth or constipation the way we do with anticholinergic drugs.”

Today on WebMD

Incontinence Women Slideshow
leaking faucet
Public restroom door sign
nachos and beer
woman holding water
Food That Makes You Gotta Go
Male Incontinence Slideshow
Mature woman standing among peers
Worried in bed
woman standing in front of restroom sign
various pills
sitting in chair